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Methods 
Between January 2004 and December 2010, 113 consecutive patients 
aged ≥75 years (median 78, range 75-87 years) underwent isolated 
MVRe (40 patients, 35%) or MVR [Tab.1]. The 5-item Cardiovascular 
Health Study frailty scale was comparable between the two groups 
(MVRe 1.3±1.03, MVR 1.4±1.1, p=0.9). Etiology included mainly 
degenerative (MVRe=38 [95%] vs MVR=38 [52%], p<0.0001) and 
rheumatic mitral regurgitation (MVRe=1 [2.5%] vs MVR=29 [26%], 
p<0.0001). Thirty-five patients (48%) in the MVR group presented 
annular calcifications (vs 8 [20%] in the MVRe; p=0.004). Eleven 
patients (9.7%) underwent MVR after at least one attempt of MVRe 
[Tab.2]. Mean follow-up (100% complete) was 53.7 months. Quality of 
life (QoL) was assessed preoperatively and at follow-up by SF-12 test. 
Background and Objective 
Mitral valve repair (MVRe) has overall advantages over replacement 
(MVR) in the management of valve regurgitation. Complex MVRe 
however might impair myocardial protection and enhance the 
drawbacks of a long cardiopulmonary bypass time, thus affecting the 
outcomes in elderly frail patients. We compared MVRe to MVR in 
patients aged 75 years or older, evaluating survival, valve-related 
outcomes and self-perception of well-being. 
Conclusions 
MVR and MVRe can be performed in elderly patients with acceptable in-hospital and mid-term mortality. MVRe performed at this age appears 
advisable whenever the likelihood of a successful procedure is expected, since replacement performed after one or more attempts is associated 
with an unacceptable mortality. MVR and MVRe survivors experience similar QoL and freedom from valve-related events within 5-years. 
- 
Results 
Overall in-hospital mortality was 8.2% (6 pts, all in the MVR group; 
p=0.088). Four out of 6 deaths occurred in patients after at least one 
attempt of MVRe [Fig.1]. At logistic regression analysis, age (p=0.04), 
EF ˂40% (p=0.02) and cross-clamp time (p=0.01) increased the risk of 
in-hospital mortality, whereas type of procedure did not (p=NS). 




i l t 5 and 10 years was 80.7±6.7% and 50.5±11.6% for MVRe, and 66.6±6.5% and 38.6±10.4% for MVR, respectively (p=0.08) [Fig.2A]. 
Freedom from reoperation and endocarditis at 5 and 10 years were over 90% for both groups (p=NS) [Fig.2B-C]. No MVR patients showed 
structural valve degeneration at follow-up. QoL showed no differences between MVRe and MVR groups for Physical (PH) and Mental Health (MH) 
Composite Scores preoperatively (PH 40.4±5.7 vs 38.6±7.8; p=0.2; MH 48.3±12.1 vs 49.2± 10; p=0.69, respectively) and at follow-up (PH 44.2±7.2 
vs 43.5±8.1; p=0.44; MH 53.1±11.1 vs 55.3 ±9.4; p=0.31, respectively) [Tab.3]. MV Replacement was not recognized as a risk factor for late 
mortality at propensity-adjusted multivariable analysis  calculated with the ANCOVA method (Odds Ratio 1.3, Standard Error 0.58, p Value 0.65). 
 
